Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

Home
/
update
/
details

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

NextEdge Admin

06 Jan 2025

2 min 32 sec

Portage Biotech, a clinical-stage immuno-oncology company, has announced the re-launch of its wholly owned subsidiary as Cyncado Therapeutics™, an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed CEO and will lead efforts to secure external financing and advance the clinical development of A2a and A2b receptor antagonists.

Cyncado’s therapeutics are designed for high potency, selectivity, and optimized binding, ensuring robust and sustained inhibition of immune suppression signals in the tumor microenvironment. The company’s dual administration strategy leverages complementary mechanisms of A2a and A2b antagonists, enhancing the immune response and overcoming tumor immune evasion. This approach has the potential to significantly improve the efficacy of immuno-oncology therapies and provide well-tolerated treatment options for cancer patients.

Molloy expressed confidence in the adenosine pathway’s potential and emphasized the promising clinical data supporting Cyncado’s assets. He is committed to driving these programs toward proof-of-concept studies, with the goal of delivering transformative treatments for patients.

Alex Pickett, CEO of Portage Biotech, highlighted that relaunching Cyncado as an independent entity will accelerate clinical progress and maximize value for Portage shareholders. He praised Molloy’s deep expertise in adenosine receptor biology and extensive biotech industry experience, which will be instrumental in advancing Cyncado’s innovative pipeline.

Cyncado Therapeutics is dedicated to establishing adenosine receptor antagonists as next-generation cancer immunotherapies, leveraging their unique mechanisms to enhance the immune system’s ability to fight cancer. Portage Biotech remains committed to developing novel biologics that transform oncology treatment and improve patient outcomes.